AVONDALE, Pa., Nov. 4, 2025 /PRNewswire/ -- CQ Medical is pleased to announce the appointment of Michael Galbus as Chief Executive Officer. Michael previously served as Chief Operating Officer, where he played a key role in enhancing operational performance, advancing the company's growth strategy, and building trust across the executive team while championing the growth and development of his team members.
A cancer survivor, Michael has a deeply personal connection to CQ Medical's mission of improving care and outcomes for patients and clinicians. He is recognized for his collaborative leadership style, sharp strategic mindset, and ability to turn ambitious goals into measurable results. Over the past several years, he has consistently fostered innovation, execution, and team development across the organization.
Michael brings more than 30 years of leadership experience across highly regulated industries, including aerospace, building products, chemicals, and medical devices. He has learned to quickly identify what makes organizations in different sectors succeed and has applied those insights to deliver performance and growth. His leadership journey has included senior roles at global companies such as Dow Inc., Saint-Gobain, Zodiac Aerospace, and ACTEGA, culminating in his appointment as CEO of CQ Medical. He holds a bachelor's degree in mechanical engineering from the University of Delaware and an MBA from Purdue University.
As CEO, Michael will focus on developing strategy and supporting teams in creating actionable operating plans, advancing the company's acquisition and integration efforts, and reinforcing a culture of trust, accountability, and innovation.
"CQ Medical has a unique opportunity to innovate in ways that directly impact patients and those who care for them," said Michael. "I look forward to building on the strong foundation we have created, partnering with our teams and customers worldwide, and continuing to deliver on our mission."
Michael and his wife Crystal live in the greater Philadelphia area, where they have raised their three children: Connor, Carter, and Madelyn. Outside of work, he enjoys running, restoring classic cars, and following collegiate and professional sports. He values the same qualities in these pursuits and in family life as he does at work: commitment, resilience, and celebrating milestones together.
Mike Sutter, CQ Medical's outgoing CEO, has been named Chairman of CQ Medical's Board of Directors, allowing him to continue his strategic contributions to the company in a new capacity. "I'm excited to transition into a new role at CQ Medical so we can continue the progress we've made as a team over the past several years. Under Michael's leadership, I believe the company is poised to accelerate growth and realize our full potential to innovate and deliver the best outcomes for patients."
About CQ Medical
As the global leader in patient radiotherapy positioning and healthcare innovation, CQ Medical unites intelligence (IQ) and empathy (EQ) to define its unique Care Quotient (CQ). Guided by this philosophy, the company transforms ideas into innovations that advance precision, elevate technology, and empower medical excellence for improved patient outcomes.
For additional information, please visit CQmedical.com or connect with CQ Medical on LinkedIn and Facebook.
COPYRIGHT © 2025 CQ Medical. All rights reserved. CQ Medical is a registered trademark of CQ Medical.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CQ Medical® Appoints Michael Galbus as Chief Executive Officer, Mike Sutter as Chairman of the Board of Directors
LAS VEGAS, Jan. 17, 2026 /PRNewswire/ -- At CES 2026, Flowtica was not the loudest presence on the show floor. Over the course of the week, however, the Singapore-based AI company became one of the most closely watched, drawing sustained attention from media, investors, and industry observers.
That attention has now translated into availability. Following its appearance as a CES 2026 Innovation Award Honoree, Flowtica has officially opened sales of Flowtica Scribe, its AI recording pen that quietly stood out in a field dominated by phone-dependent and screen-heavy solutions.
Flowtica Scribe did not make its first public appearance at CES. The product launched on Kickstarter several months earlier, where it attracted thousands of users and established early validation. CES marked a different stage for the company. The focus shifted away from introduction and toward closer examination, with many observers asking whether the idea could hold up beyond early enthusiasm.
Throughout the exhibition, Flowtica's booth at Eureka Park became a steady meeting point for investors and journalists. Conversations rarely centered on specifications or feature lists. Instead, discussions focused on a more fundamental question: whether AI recording tools are beginning to converge on forms that genuinely fit into professional life.
Flowtica's answer was visible in its choice of form. By embedding AI into a pen, an object already accepted in boardrooms, consultations, investor meetings, and sales conversations, the company avoided many of the social and practical frictions that continue to limit phone-based recorders. The result was a device that felt less like a new category of gadget and more like a natural extension of existing behavior.
This restraint is deliberate. Flowtica Scribe is designed to remain unobtrusive, with no screen and no demand for user attention during conversations. Recording, organization, and interpretation take place quietly in the background, allowing users to remain focused on the discussion itself. Among on-site observers, this approach positioned Flowtica as one of the more pragmatic entrants in an increasingly crowded AI recording market.
Hardware, however, represents only part of Flowtica's differentiation. The company places equal emphasis on what happens after recording ends. Its AI functions as a continuously evolving insight system that can operate autonomously while remaining responsive to clear user guidance when needed. Over time, it adapts to individual working rhythms and priorities, shifting the emphasis from capturing everything to identifying what truly matters.
Rather than simply storing conversations, Flowtica helps determine which moments should be retained, revisited, and translated into next actions. Key insights are designed to integrate naturally with existing productivity tools, including calendars and task systems, allowing them to fit into established workflows rather than compete with them.
As interest in Flowtica Scribe built during CES, one question surfaced repeatedly. When would the product be available beyond the show floor?
With sales now officially open through Flowtica's website, the company moves from exhibition attention to real-world deployment. For Flowtica, this moment appears less like a conclusion and more like a transition, from being observed to being used.
As the AI recording market continues to mature, competition is shifting away from novelty and early adoption toward durability. The defining question is no longer whether a system can record conversations, but whether it can remain useful over time.
Flowtica enters this next phase with an approach that is measured and quietly confident, placing its bet not on spectacle, but on long-term relevance.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
The AI Recording Pen That Turned Heads at CES Is Finally for Sale
